RecruitingGastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Eligible age

18+ yrs

Accepts

All genders

Locations

35 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Sponsor: AstraZeneca

You may qualify if…

✓ Capable of giving signed informed consent
✓ Participant must be 18 years or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
✓ Previously untreated histologically documented unresectable, locally advanced, or metastatic gastric, GEJ, or distal esophagus (distal third of the esophagus) adenocarcinoma
✓ Positive CLDN18.2 expression, as determined prospectively by central IHC testing
✓ Confirmed PD-L1 CPS status by central IHC testing and ICI eligibility per investigator judgement is required to determine cohort eligibility as described below:
✓ 1. Cohort 1: PD-L1 positive as determined by central IHC testing and the participant is deemed ICI eligible per investigator judgement.
✓ 2. Cohort 2: PD-L1 negative as determined by central IHC testing OR the participant is ICI ineligible
✓ ECOG performance status of 0 or 1 with no deterioration to \> 1 over the previous 2 weeks prior to baseline at screening and prior to randomisation.

You may not qualify if…

✕ Known HER2-positive status
✕ Significant or unstable gastric bleeding and/or untreated gastric ulcers.
✕ Active or history of autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment or assessed by investigator as not appropriate to participate due to undue risk are excluded.
✕ CNS pathology
✕ Clinically significant pleural effusions or ascites and/or pleural effusions or ascites that require drainage, peritoneal shunt, or indwelling catheter/drain.
✕ Require parenteral nutrition support due to gastric or gastrointestinal obstruction.
✕ Peripheral neuropathy, sensory or motor, ≥ CTCAE Grade 2 at screening.
✕ Persistent toxicities caused by previous anticancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.